Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9589665rdf:typepubmed:Citationlld:pubmed
pubmed-article:9589665lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0037663lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0003765lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0020615lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0039593lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0011155lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:9589665lifeskim:mentionsumls-concept:C0815016lld:lifeskim
pubmed-article:9589665pubmed:issue5lld:pubmed
pubmed-article:9589665pubmed:dateCreated1998-6-4lld:pubmed
pubmed-article:9589665pubmed:abstractTextThere is now wide consensus that, within an appropriate clinical context, GH deficiency (GHD) in adults must be shown biochemically by provocative testing of GH secretion and that appropriate cut-off limits have to be defined for each provocative test. Insulin-induced hypoglycemia (ITT) is indicated as the test of choice, and severe GHD, to be treated with recombinant human GH replacement, is defined by a GH peak response to ITT of less than 3 micrograms/L. GHRH + arginine (GHRH + ARG) is one of the most promising tests in alternative to ITT. In fact, it has been reported as a potent, reproducible, and age-independent test and that it is able to distinguish between GHD and normal adults. The aim of the present study was to compare the GH response to ITT and GHRH + ARG in a large group of hypopituitary adults (n = 40; 29 male and 11 female; age: 36.4 +/- 2.1 yr). The third centile limit of the peak GH response to ITT has been reported as 5 micrograms/L, whereas in our lab, that to GHRH + ARG is 16.5 micrograms/L. In hypopituitary adults, the mean peak GH response to ITT (1.5 +/- 0.2 micrograms/L, range: 0.1-8.5 micrograms/L) was lower (P < 0.001) than that to GHRH + ARG (3.0 +/- 0.4 micrograms/L, range 0.1-12.0 micrograms/L), though there was positive correlation (r = 0.61, P < 0.001) between the GH responses to the 2 tests. The peak GH response to GHRH + ARG, but not that to ITT, was positively (though weakly) associated with insulin-like growth factor-I levels (r = 0.35, P < 0.03). Childhood and adult onset GHD patients, as well as patients with single and multiple pituitary insufficiencies, had similar peak GH responses to ITT or GHRH + ARG. Analyzing individual GH responses, 4/40 (10%) of the hypopituitary patients had GH peaks higher than 5 micrograms/L after ITT; moreover, 3 other patients (7%) had GH peaks, after ITT, higher than 3 micrograms/L. On the other hand, after GHRH + ARG, all patients had GH peaks lower than 16.5 micrograms/L, whereas 21/40 (52.5%) had GH peaks higher than 3 micrograms/L. Because 3 micrograms/L is the arbitrary cut-off for ITT, the third centile limit of which is 5 micrograms/L, we arbitrarily considered 9 micrograms/L as the cut-off point for GHRH + ARG. It is noteworthy that 37/40 (92.5%) patients had a GH peak, after GHRH + ARG, below this limit. In conclusion, our present results confirm that the ITT test is a reliable provocative test for the diagnosis of adult GHD, whereas they show that the GHRH + ARG test is, at least, as sensitive as the ITT test (provided that appropriate cut-off limits are considered). Note that even the arbitrary cut-off point below which severe GHD is demonstrated has to be appropriate to the potency of the test.lld:pubmed
pubmed-article:9589665pubmed:languageenglld:pubmed
pubmed-article:9589665pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9589665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9589665pubmed:statusMEDLINElld:pubmed
pubmed-article:9589665pubmed:monthMaylld:pubmed
pubmed-article:9589665pubmed:issn0021-972Xlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:CamanniFFlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:GhigoEElld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:ArvatEElld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:AimarettiGGlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:CorneliGGlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:BelloneSSlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:RazzorePPlld:pubmed
pubmed-article:9589665pubmed:authorpubmed-author:BaffoniCClld:pubmed
pubmed-article:9589665pubmed:issnTypePrintlld:pubmed
pubmed-article:9589665pubmed:volume83lld:pubmed
pubmed-article:9589665pubmed:ownerNLMlld:pubmed
pubmed-article:9589665pubmed:authorsCompleteYlld:pubmed
pubmed-article:9589665pubmed:pagination1615-8lld:pubmed
pubmed-article:9589665pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:meshHeadingpubmed-meshheading:9589665-...lld:pubmed
pubmed-article:9589665pubmed:year1998lld:pubmed
pubmed-article:9589665pubmed:articleTitleComparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.lld:pubmed
pubmed-article:9589665pubmed:affiliationDepartment of Internal Medicine, University of Turin, Italy.lld:pubmed
pubmed-article:9589665pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9589665pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9589665pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9589665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9589665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9589665lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9589665lld:pubmed